Neoplasms

All Conditions

Infections

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Papilloma

Virus Diseases

Warts

Communicable Diseases

Papillomavirus Infections

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

All Drugs and Chemicals

Vaccines

Immunologic Factors

Patient receive 0.1 ml of quadrivalent HPV vaccine intralesional every two weeks

Patient received 0.1 ml of bivalent HPV vaccine intralesional once every two weeks

Patient received 0.1 ml of intralesional saline once every two weeks

Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine

Bivalent Human Papilloma Virus Vaccine

intralesional into the largest warts every two weeks

Saline

Warts are common, benign, epidermal proliferations caused by HPV infecting skin and mucous membranes. Treatment of warts poses a true challenge despite existing variable therapeutic modalities, whether destructive or immunotherapeutic. Human papilloma virus (HPV) vaccines are FDA approved for the prevention of genital warts and wart related precancerous and cancerous lesions but they are not indicated for treatment of preexisting warts yet

Approximately 35% of viral warts tend to be recalcitrant either showing no response to treatment or having prompt recurrences after treatment, causing frustration for both patients and physicians. Success rates vary significantly across patients and across different therapeutic interventions ranging from 7% to 90%.

Immunotherapy is proposed to enhance virus recognition by the cell mediated immunity, which allows the clearance of both treated and untreated warts and helps to prevent recurrences through induction of a long-term acquired immunity to HPV.

Few reports suggest the possibility of using quadrivalent or bivalent HPV vaccines as therapeutic modality rather than only preventive modality. This is a randomized controlled study to assess the efficacy and safety of quadrivalent and bivalent HPV vaccines in the treatment of warts

Gardasil Versus Cervarix in the Treatment of Warts

Quadrivalent and Bivalent Human Papilloma Virus Vaccines in the Treatment of Common Recalcitrant Warts

The percentage of patients in each group achieving complete, partial or no response at the end of the treatment sessions

Immediate adverse events recorded by the treating physician within 1 hour post injection

Delayed adverse events reported by the patients in between sessions

Percentage of patients experiencing recurrences in each group

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Gardasil Versus Cervarix in the Treatment of Warts	NCT05383625	Verruca Viral	Quadrivalent Hu... Bivalent Human ... Saline	18 Years -	Zagazig University
Gardasil Versus Cervarix in the Treatment of Warts	NCT05383625	Verruca Viral	Quadrivalent Hu... Bivalent Human ... Saline	18 Years -	Zagazig University

Spots Global Cancer Trial Database for bivalent human papilloma virus vaccine